Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) issued its earnings results on Wednesday. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.31) by $0.15, Zacks reports. The business had revenue of $11.13 million during the quarter, compared to the consensus estimate of $9.87 million. Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%.
Capricor Therapeutics Stock Down 10.4 %
NASDAQ CAPR traded down $1.50 during mid-day trading on Friday, hitting $12.86. The stock had a trading volume of 2,657,651 shares, compared to its average volume of 1,388,753. Capricor Therapeutics has a 52-week low of $3.52 and a 52-week high of $23.40. The company has a market cap of $584.74 million, a price-to-earnings ratio of -12.13 and a beta of 4.10. The company has a 50 day simple moving average of $14.06 and a 200 day simple moving average of $14.62.
Wall Street Analysts Forecast Growth
CAPR has been the subject of a number of analyst reports. Cantor Fitzgerald reissued an "overweight" rating and set a $30.00 target price on shares of Capricor Therapeutics in a research note on Thursday. HC Wainwright reissued a "buy" rating and set a $77.00 target price on shares of Capricor Therapeutics in a research note on Monday, March 17th. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $34.50.
Check Out Our Latest Stock Analysis on Capricor Therapeutics
About Capricor Therapeutics
(
Get Free Report)
Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
See Also
Before you consider Capricor Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Capricor Therapeutics wasn't on the list.
While Capricor Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
